Skip to main content

Latest from Medicine Matters oncology

Latest headlines

22-10-2019 | Renal cell carcinoma | ESMO 2019 | News

Benefit of nivolumab–tivozanib, nivolumab beyond progression shown in metastatic RCC

Studies presented at the ESMO 2019 Congress propose that patients with metastatic renal cell carcinoma may benefit from a combination of nivolumab and the VEGFR tyrosine kinase inhibitor tivozanib, or by continuing with single-agent nivolumab past initial disease progression.

22-10-2019 | Screening | News

Life-gained selection approach could expand benefits of lung cancer screening

Using a life–years gained approach to select patients for lung cancer screening could maximize its benefits for current and ex-smokers who have both a high risk for lung cancer and a long life expectancy, US research suggests.

21-10-2019 | Lung cancer | News

BCG vaccination linked to reduced incidence of lung cancer

Receipt of the Bacillus Calmette-Guérin vaccine may reduce the risk for developing lung cancer, suggests a secondary analysis of a clinical trial conducted in American–Indian and Alaska Native populations.

21-10-2019 | Renal cell carcinoma | ESMO 2019 | News

Treatment-free survival proposed as novel RCC immunotherapy endpoint

Time spent off treatment could be used as a novel clinical trial endpoint for patients undergoing renal cell carcinoma immunotherapy, suggest study findings reported at the ESMO Congress 2019 in Barcelona, Spain.

18-10-2019 | Renal cell carcinoma | ESMO 2019 | News

KEYNOTE-427 updates confirm pembrolizumab benefit for advanced RCC

The latest findings from the KEYNOTE-427 trial add to the efficacy evidence for first-line pembrolizumab against advanced or metastatic renal cell carcinoma regardless of histology.

18-10-2019 | Non-small cell lung cancer | News

Electronic nose predicts PD-1 inhibitor response

An electronic nose can predict if patients with advanced non-small-cell lung cancer will respond to immune checkpoint inhibitor therapy by analyzing the composition of volatile organic compounds in patients’ exhaled breath, say researchers.

Feature content

09-10-2019 | Non-small cell lung cancer | Editorial | Article

Current therapies for advanced NSCLC: The role of maintenance therapy in an immunotherapy world

Thomas Stinchcombe (Duke Cancer Institute, USA) examines the development of maintenance regimens and where they fit as immunotherapy continues to change treatment paradigms for NSCLC.

07-10-2019 | Prostate cancer | Video | Article

Expert comment: The STAMPEDE study

Eleni Efstathiou shares her views on the STAMPEDE analysis indicating that docetaxel may be an option for hormone-naïve prostate cancer regardless of metastatic disease burden (2:16).

07-10-2019 | Renal cell carcinoma | Video | Article

Researcher comment: A novel CXCR4 inhibitor for RCC and a novel immunotherapy endpoint

David McDermott talks through his renal cell carcinoma research exploring the use of a novel oral CXCR4 inhibitor and treatment-free survival as an alternative endpoint for immunotherapy trials (4:03).

This independent video interview was supported by an educational grant from Pfizer and Merck KGaA

Get the latest content delivered to your inbox

Register with Medicine Matters to start receiving our weekly newsletter now!

Image Credits